溶性泌尿酸酶等离子体激活受体是不补偿性肝硬化症的预后生物标志物
Sven Lamatsch1, Mohsin Hassan1, Kai Kappert2,3
1Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hepatology & Gastroenterology, Campus Virchow-Klinikum and Campus Charité Mitte, Berlin, Germany.
JHEP reports : innovation in hepatology
|February 18, 2026
概括
溶性泌尿酸酶等离子体激活受体 (suPAR) 是一个有前途的生物标志物,用于预测脱偿性肝硬化中的死亡率和疾病进展. 升高的suPAR水平表明肝脏衍生的全身炎症,可以补充现有的评分系统,以更好地管理患者.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 生物标志物发现发现
- 炎症研究 炎症研究
背景情况:
- 肝硬化导致显著的发病率和死亡率,需要更好的预后标志物.
- 急性至慢性肝衰竭 (ACLF) 是肝硬化的一种严重并发症.
- 溶性泌尿酸酶等离子体激活受体 (suPAR) 与肝脏疾病中的全身炎症有关.
研究的目的:
- 评估suPAR作为慢性肝病的预后标志物.
- 评估suPAR水平与疾病严重程度和肝硬化结果的相关性.
- 为了研究suPAR在肝脏特定炎症中的作用.
主要方法:
- 在导出和验证队列中测量了suPAR水平,包括健康对照组和肝硬化,脱补偿和ACLF患者.
- 利用肝损伤的小鼠模型将suPAR水平与肝脏PAR表达相关联.
- 采用单细胞RNA测序来分析健康对照和肝硬化患者免疫细胞中的UPAR表达.
主要成果:
- SuPAR水平与疾病严重程度 (肌素,胆红素,MELD得分) 和住院时间的标志物有显著的相关性.
- 升高的suPAR与增加的住院死亡率,ICU治疗,90天死亡率和ACLF进展有关.
- SuPAR水平≥14.0 ng/ml独立预测了无补偿性肝硬化90天死亡率,这一发现在第二个队列中得到了验证.
结论:
- SuPAR作为一个有价值的生物标志物,用于预测脱补偿性肝硬化病的结果,反映系统性和肝脏炎症.
- suPAR水平与疾病进展,器官功能障碍和死亡率有关.
- suPAR可以补充像MELD这样的既定评分系统,以改善晚期肝病患者的管理.
相关概念视频
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
212
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
212
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
942
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
942
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
622
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
622
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
357
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
357